IRA Drug Price Negotiation: Impact on Pharma Valuation and Strategy

Introduction

The Inflation Reduction Act's Medicare drug price negotiation provisions represent the most significant change to US pharmaceutical pricing policy in decades. For healthcare bankers, the IRA is not just a political risk factor; it is a structural shift that changes how pharma companies are valued, how pipeline assets are prioritized, and which M&A targets are most attractive.

The IRA allows Medicare to negotiate "Maximum Fair Prices" for drugs that meet specific criteria:

Maximum Fair Price (MFP)

The ceiling price that Medicare may negotiate for eligible drugs under the IRA. The MFP cannot exceed a percentage of the drug's non-federal average manufacturer price (non-FAMP): 75% for drugs 7-11 years post-approval, 65% for drugs 12-15 years, and 40% for drugs 16+ years. The negotiation applies to Part D (outpatient pharmacy) drugs initially, with Part B (physician-administered) drugs eligible starting in 2028.

Eligibility timeline: A drug becomes eligible for negotiation when it has been approved for at least 7 years (small molecules) or 11 years (biologics), has no generic or biosimilar competition, and is among the highest-spend drugs in Medicare. The number of drugs subject to negotiation increases from 10 in 2026 to 20 per year by 2029.

The selection process: CMS identifies the highest-spend Medicare drugs that meet the eligibility criteria. The manufacturer and CMS negotiate a Maximum Fair Price, with CMS having significant leverage (the penalty for refusing to negotiate is an excise tax starting at 186% of the drug's revenue and escalating to 1,900%).

The most strategically significant provision of the IRA is the 4-year timing differential between small molecules and biologics. Small molecules become eligible for negotiation at 7 years post-approval. Biologics become eligible at 11 years. This 4-year gap, which the industry calls the "pill penalty," creates a systematic disadvantage for small molecule drugs.

The pharma industry is adapting to the IRA through several strategic shifts:

Biologics preference. The pill penalty accelerates the industry's existing trend toward biologic development. Companies are prioritizing biologic candidates (antibodies, ADCs, cell therapies, gene therapies) over small molecules in R&D portfolio decisions.

Orphan drug focus. Drugs with orphan designations for a single approved indication are exempt from IRA negotiation. This increases the attractiveness of rare disease programs and has driven up M&A premiums for biotech companies with orphan-designated assets.

Earlier pricing optimization. Companies are front-loading commercial revenue by optimizing launch pricing and maximizing volume growth in the years before negotiation eligibility, rather than following the traditional strategy of gradual price increases over the product lifecycle.

Accelerated indication expansion. Companies are pursuing additional indications more aggressively to maximize the commercial value of products during the unencumbered pricing period.

When building pharma valuation models post-IRA, healthcare bankers adjust revenue projections for eligible products:

1. Identify eligible products based on approval date, drug type (small molecule vs. biologic), and orphan drug status 2. Calculate negotiation eligibility date (approval date + 7 years for small molecules, + 11 years for biologics) 3. Apply MFP discount to revenue projections starting at the eligibility date (typically 25-60% reduction from pre-negotiation pricing, depending on the applicable MFP ceiling) 4. Adjust terminal value assumptions to reflect the compressed revenue tail

The next two articles cover specific pharma sub-segments: generic pharma and specialty pharma, each with distinct business models and valuation dynamics.